
Plus Therapeutics Stock Gains As FDA Clears REYOBIQ IND Application To Treat Pediatric Brain Cancers
Shares of Plus Therapeutics, Inc. (PSTV) were gaining around 120% in the pre-market activity on the Nadsaq after the company announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug or IND application for REYOBIQTM ( …